XTEN

Enterprise Connect 2024 Brought the Enterprise Communications and Customer Experience Community Together to Improve Business Communications/CX

Retrieved on: 
Thursday, March 28, 2024
Software, Networks, Other Communications, Public Relations, Investor Relations, Data Management, Communications, Technology, Other Technology, Diamond, Theta, Jabra, AVAYA, AT&T, Labs, Learning, Unified communications management, CX, TransUnion, Enterprise, CallMiner, Goto, Zoom, Spotlight Awards, USAN, Telefónica, Emulator, Lunch, Cisco Webex, TD SYNNEX, Microsoft, Intrado, Cyber, BICS, Communication, ZOOM, IRIS, Medtronic, RingCentral, AWS, Uniphore, Woman, ViewSonic, Cargill, Exhibition, Singlewire Software, Gold, RSI, HP, Continuant, Organization, XTEN, Poly, AI, Cisco, Amazon Web Services, ASC, Security, Light-year, Syniverse, Consultant, Silver, Verizon Business, UC, AudioCodes, Motus, Electronics, Charter Communications, Ecosystem, Platinum, Delta Air Lines, Management

Enterprise Connect , the leading conference and exhibition for enterprise communications and customer experience (CX), brought IT decision-makers together to improve business communications and CX.

Key Points: 
  • Enterprise Connect , the leading conference and exhibition for enterprise communications and customer experience (CX), brought IT decision-makers together to improve business communications and CX.
  • “We had an extraordinary week bringing the industry together in person in Orlando and digitally,” said Eric Krapf, General Manager, Enterprise Connect.
  • “For more than 30 years, Enterprise Connect has brought corporate IT decision makers together with industry vendors, analysts, consultants, and channel partners to focus on the issues central to enterprise communications.
  • The Best of Enterprise Connect awards program recognized excellence and innovation in the enterprise communications and customer experience industry.

XTEN-AV LLC Secures Strategic Investment from Resideo Technologies

Retrieved on: 
Wednesday, January 31, 2024
ADI, Growth, Pro, ADI Global Distribution, AV, Machine learning, Safety, Artificial intelligence, SVP, Documentation, XTEN

Union City, California--(Newsfile Corp. - January 31, 2024) - XTEN-AV LLC, a leading Pro AV (Professional Audio-Visual) design and proposal software provider, announces receiving a minority investment from Resideo Technologies, Inc.

Key Points: 
  • Union City, California--(Newsfile Corp. - January 31, 2024) - XTEN-AV LLC, a leading Pro AV (Professional Audio-Visual) design and proposal software provider, announces receiving a minority investment from Resideo Technologies, Inc.
  • This investment is a significant milestone for XTEN-AV and sets the stage for expanded growth across the Pro AV industry.
  • Resideo Technologies, Inc. is a leading global manufacturer and developer of technology-driven products that provide critical comfort, energy management, and safety and security solutions.
  • "This strategic investment not only strengthens our position in the market but also signifies a shared vision of advancing the Pro AV industry through innovation and efficiency."

Sanofi to acquire Amunix immuno-oncology pipeline with next generation Conditionally Activated Biologics

Retrieved on: 
Tuesday, December 21, 2021
XTEN, D, Entrepreneurship, Sanofi, Health, Adoption, Pain, Doctor of Philosophy, Technology, CEO, Acquisition, Cancer, Vaccine, Cytokine release syndrome, Weil, Gotshal & Manges, Research, Disease, Centerview Partners, Tumor microenvironment, LLC, Hart–Scott–Rodino Antitrust Improvements Act, Toxicity, Immune system, TCE, Cytokine, Patient, Achievement, Bi-specific T-cell engager, Pharmaceutical industry, Medical imaging

Under the terms of the agreement, Sanofi will acquire Amunix for an upfront payment of approximately $1 billion and up to $225 million upon achievement of certain future development milestones.

Key Points: 
  • Under the terms of the agreement, Sanofi will acquire Amunix for an upfront payment of approximately $1 billion and up to $225 million upon achievement of certain future development milestones.
  • This acquisition demonstrates our ongoing commitment to investing in promising research and discovery platforms, said John Reed, M.D., Ph.D., Global Head of Research & Development, Sanofi.
  • We are excited to rapidly advance Amunixs promising pipeline and to combine their innovative candidate medicines with complementary molecules in Sanofis immuno-oncology portfolio.
  • With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.